Study to Learn About the Safety and Effectiveness of Crizotinib in Participants With Tumors, Except Non-Small Cell Lung Cancer, That Are Positive for Anaplastic Lymphoma Kinase (ALK).

Study to Learn About the Safety and Effectiveness of Crizotinib in Participants With Tumors, Except Non-Small Cell Lung Cancer, That Are Positive for Anaplastic Lymphoma Kinase (ALK)

Phase 1b Open-Label Study of the Safety and Clinical Activity of Crizotinib (PF-02341066) in Tumors With Genetic Events Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus

Category & Conditions: Cancer

Medicine: XALKORI®(CRIZOTINIB)

ClinicalTrials.gov Identifier (NCT): NCT01121588

Protocol ID: A8081013

Print Download

Open Plain Language Summary Result: Click here